Gentler chemo combo shows promise for older leukemia patients
NCT ID NCT07153796
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This phase 2 trial is testing a drug called blinatumomab, given as a shot under the skin, together with a milder chemotherapy regimen for people aged 60 and older (or younger adults who are too frail for standard chemo) with a type of blood cancer called B-cell acute lymphoblastic leukemia. The study aims to see if this combination is safe and effective. Only 3 participants have been enrolled so far, so the results are very early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blinatumomab (given as a shot under the skin) combined with low-intensity chemotherapy
What this could lead to
If successful, this could offer a gentler treatment option for older or frail patients with B-cell acute lymphoblastic leukemia, potentially improving outcomes with fewer harsh side effects.
What could go wrong
This is a very early phase 2 trial with only 3 participants enrolled so far, so results are highly preliminary. The combination may still cause serious side effects or may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.